HRP20191955T1 - Orvepitant za liječenje kroničnog pruritusa - Google Patents
Orvepitant za liječenje kroničnog pruritusa Download PDFInfo
- Publication number
- HRP20191955T1 HRP20191955T1 HRP20191955TT HRP20191955T HRP20191955T1 HR P20191955 T1 HRP20191955 T1 HR P20191955T1 HR P20191955T T HRP20191955T T HR P20191955TT HR P20191955 T HRP20191955 T HR P20191955T HR P20191955 T1 HRP20191955 T1 HR P20191955T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- pruritus
- use according
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title claims 6
- 230000001684 chronic effect Effects 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000017520 skin disease Diseases 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 206010048768 Dermatosis Diseases 0.000 claims 3
- XWNBGDJPEXZSQM-VZOBGQTKSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C XWNBGDJPEXZSQM-VZOBGQTKSA-N 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 239000002085 irritant Substances 0.000 claims 2
- 231100000021 irritant Toxicity 0.000 claims 2
- 229950006784 orvepitant Drugs 0.000 claims 2
- AXYZWPCBZJJNSU-XYJFISCASA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid Chemical compound CC1=CC(F)=CC=C1[C@@H]1N(C(O)=O)CC[C@H](N2C[C@H]3N(C(CC3)=O)CC2)C1 AXYZWPCBZJJNSU-XYJFISCASA-N 0.000 claims 1
- IPACOHTZCSBGBV-WUXDIRCFSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C IPACOHTZCSBGBV-WUXDIRCFSA-N 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 210000004706 scrotum Anatomy 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electrically Operated Instructional Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Claims (7)
1. [1-(R)-(3,5-bis-trifluorometil-fenil]-etil]-metilamid 2-(R)-(4-fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju kroničnog pruritusa kao posljedice ili povezanog s upalnim dermatozama.
2. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s patentnim zahtjevom 1, naznačen time, što je upalna dermatoza odabrana od atopijskog dermatitisa/ekcema, psorijaze, nadražajnog/kontaktnog dermatitisa, nadražajnog/kontaktnog ekcema, urtikarije, suhe kože, neželjenih reakcija na lijek, ožiljaka, pruritusa anusa, pruritusa skrotuma, pruritusa vulve i nevidljivih dermatoza.
3. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time, što je upalna dermatoza atopijski dermatitis/ekcem.
4. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time, što je upalna dermatoza psorijaza.
5. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, što je farmaceutski prihvatljiva sol spoja maleat.
6. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, što je spoj orvepitant maleat u bezvodnom kristalnom obliku.
7. Farmaceutski pripravak za uporabu u liječenju kroničnog pruritusa kao posljedice ili povezanog s upalnim dermatozama, koji sadrži [1-(R)-(3,5-bis-trifluorometil-fenil]-etil]-metilamid 2-(R)-(4-fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili njegovu farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača ili pomoćnih tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712499P | 2012-10-11 | 2012-10-11 | |
| PCT/EP2013/071093 WO2014057003A1 (en) | 2012-10-11 | 2013-10-09 | Novel uses |
| EP13774189.8A EP2906219B1 (en) | 2012-10-11 | 2013-10-09 | Orvepitant for the treatment of chronic pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191955T1 true HRP20191955T1 (hr) | 2020-01-24 |
Family
ID=49322388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191955TT HRP20191955T1 (hr) | 2012-10-11 | 2019-10-29 | Orvepitant za liječenje kroničnog pruritusa |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9603849B2 (hr) |
| EP (2) | EP2906219B1 (hr) |
| JP (2) | JP6815728B2 (hr) |
| KR (1) | KR102202481B1 (hr) |
| CN (1) | CN104703603A (hr) |
| AU (1) | AU2013328695B9 (hr) |
| BR (1) | BR112015006051A2 (hr) |
| CA (1) | CA2884454C (hr) |
| CY (1) | CY1122313T1 (hr) |
| DK (1) | DK2906219T3 (hr) |
| EA (1) | EA201590364A1 (hr) |
| ES (1) | ES2750662T3 (hr) |
| HK (1) | HK1211486A1 (hr) |
| HR (1) | HRP20191955T1 (hr) |
| HU (1) | HUE046508T2 (hr) |
| IL (1) | IL237636B (hr) |
| LT (1) | LT2906219T (hr) |
| MX (1) | MX362879B (hr) |
| PL (1) | PL2906219T3 (hr) |
| PT (1) | PT2906219T (hr) |
| RS (1) | RS59470B1 (hr) |
| SG (1) | SG11201501867UA (hr) |
| SI (1) | SI2906219T1 (hr) |
| WO (1) | WO2014057003A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603849B2 (en) * | 2012-10-11 | 2017-03-28 | Nerre Therapeutics Limited | Uses of orvepitant |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| SI3377064T1 (sl) * | 2016-01-08 | 2019-11-29 | Nerre Therapeutics Ltd | Orvepitant za zdravljenje kroničnega kašlja |
| CN109640981A (zh) * | 2016-06-29 | 2019-04-16 | 曼隆治疗公司 | 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途 |
| TWI805601B (zh) | 2017-08-11 | 2023-06-21 | 南韓商愛茉莉太平洋股份有限公司 | 醫藥組成物及抑制其形成結晶的方法 |
| WO2021046350A1 (en) * | 2019-09-05 | 2021-03-11 | Incyte Corporation | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
| JP7478894B1 (ja) | 2022-11-30 | 2024-05-07 | 花王株式会社 | 痒みの予防又は改善剤 |
| JP7478895B1 (ja) | 2022-11-30 | 2024-05-07 | 花王株式会社 | 痒みの予防又は改善剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6203803B1 (en) | 1994-12-14 | 2001-03-20 | Societe L'oreal S.A. | Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| FR2728265A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p dans une composition pharmaceutique |
| EP1295599A1 (en) | 2001-09-21 | 2003-03-26 | Boehringer Ingelheim International GmbH | Method for the treatment of prevention of atopic dermatitis |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| EP1594574A2 (en) * | 2003-01-27 | 2005-11-16 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
| GB0522061D0 (en) | 2005-10-28 | 2005-12-07 | Glaxo Group Ltd | Chemical process |
| CN101970488B (zh) * | 2007-12-07 | 2014-06-18 | 津莫吉尼蒂克斯公司 | 对il-31特异的人源化抗体分子 |
| GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| BRPI1008008A2 (pt) * | 2009-02-24 | 2016-02-23 | Novartis Ag | usos de antagonistas do receptor de nk |
| WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
| RU2631319C2 (ru) | 2012-02-22 | 2017-09-21 | Лео Фарма А/С | Новые соединения - антагонисты рецептора нейрокинина 1 |
| US9603849B2 (en) * | 2012-10-11 | 2017-03-28 | Nerre Therapeutics Limited | Uses of orvepitant |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
-
2013
- 2013-10-09 US US14/426,620 patent/US9603849B2/en active Active
- 2013-10-09 WO PCT/EP2013/071093 patent/WO2014057003A1/en active Application Filing
- 2013-10-09 CA CA2884454A patent/CA2884454C/en active Active
- 2013-10-09 LT LT13774189T patent/LT2906219T/lt unknown
- 2013-10-09 BR BR112015006051A patent/BR112015006051A2/pt not_active IP Right Cessation
- 2013-10-09 KR KR1020157008094A patent/KR102202481B1/ko active IP Right Grant
- 2013-10-09 HU HUE13774189A patent/HUE046508T2/hu unknown
- 2013-10-09 EP EP13774189.8A patent/EP2906219B1/en active Active
- 2013-10-09 SI SI201331608T patent/SI2906219T1/sl unknown
- 2013-10-09 EA EA201590364A patent/EA201590364A1/ru unknown
- 2013-10-09 ES ES13774189T patent/ES2750662T3/es active Active
- 2013-10-09 MX MX2015004162A patent/MX362879B/es active IP Right Grant
- 2013-10-09 JP JP2015536117A patent/JP6815728B2/ja active Active
- 2013-10-09 PL PL13774189T patent/PL2906219T3/pl unknown
- 2013-10-09 EP EP19189616.6A patent/EP3597192A1/en not_active Withdrawn
- 2013-10-09 AU AU2013328695A patent/AU2013328695B9/en active Active
- 2013-10-09 SG SG11201501867UA patent/SG11201501867UA/en unknown
- 2013-10-09 DK DK13774189T patent/DK2906219T3/da active
- 2013-10-09 PT PT137741898T patent/PT2906219T/pt unknown
- 2013-10-09 RS RSP20191395 patent/RS59470B1/sr unknown
- 2013-10-09 CN CN201380052009.0A patent/CN104703603A/zh active Pending
-
2015
- 2015-03-09 IL IL237636A patent/IL237636B/en active IP Right Grant
- 2015-12-16 HK HK15112357.5A patent/HK1211486A1/xx unknown
-
2017
- 2017-02-07 US US15/426,454 patent/US20170143711A1/en not_active Abandoned
-
2019
- 2019-03-27 US US16/365,828 patent/US20190216806A1/en not_active Abandoned
- 2019-04-08 JP JP2019073731A patent/JP6953468B2/ja active Active
- 2019-10-29 HR HRP20191955TT patent/HRP20191955T1/hr unknown
- 2019-11-05 CY CY20191101147T patent/CY1122313T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191955T1 (hr) | Orvepitant za liječenje kroničnog pruritusa | |
| HRP20190764T1 (hr) | Heterocikli sposobni modulirati odgovore t-stanica, i postupci za njihovu upotrebu | |
| MY174188A (en) | Heterocyclyl compounds | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| IN2014DN09434A (hr) | ||
| UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
| UA111588C2 (uk) | Композиція інгібітора jak для місцевого застосування | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| CL2012002621A1 (es) | Polimorfo forma i, ii, iii, iv y vi de 4-trifluorometil-n-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1h)-il)-benzamida (st-246); metodo para producirlas; composicion farmaceutica; forma de dosificacion unitaria; y metodo de tratamiento de infecciones por ortopoxvirus y de eczema vacunal. | |
| BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| BR112014018795A2 (pt) | derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase | |
| EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
| MX340574B (es) | Imidazo pirazinas. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| BR112014002915A2 (pt) | inibidores de pde4 suaves | |
| SI2729474T1 (en) | (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS | |
| EA201500368A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии | |
| EA201200799A1 (ru) | Гепатопротекторное средство | |
| RS54325B1 (en) | PHARMACEUTICAL COMPOUNDS CONTAINING BETA GALACTOSIDASE AND ALPHA GALACTOSIDASE AND THEIR USE FOR THE TREATMENT OF GASTROESOFAGEAL REFLUX DISEASE |